Clinical trial
A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions.
NCT01182194 is registered in ClinicalTrials.gov with Teva Pharmaceuticals USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions.
- Lead sponsor
- Teva Pharmaceuticals USA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2006
- Completion date
- August 31, 2006
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy